Get the Stockscreener App
1.08
2.70%
-0.03
After Hours:
1.08
Cognition Therapeutics Inc stock is traded at $1.08, with a volume of 1.80M.
It is down -2.70% in the last 24 hours and down -6.90% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$1.11
Open:
$1.12
24h Volume:
1.80M
Relative Volume:
2.13
Market Cap:
$95.34M
Revenue:
-
Net Income/Loss:
$-27.99M
P/E Ratio:
-2.2737
EPS:
-0.475
Net Cash Flow:
$-29.53M
1W Performance:
+0.00%
1M Performance:
-6.90%
6M Performance:
-18.80%
1Y Performance:
+144.57%
1-Day Range:
$1.07
$1.20
1-Week Range:
$1.0501
$1.20
52-Week Range:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.08 | 97.98M | 0 | -27.99M | -29.53M | -0.475 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ... By GuruFocus - Investing.com Canada
Cognition Therapeutics Advances Zervimesine (CT1812) for Alzheimer’s and Dementia—Clinical Results, Pipeline, and Strategic Overview - Minichart
Cognition Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Cognition Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Cognition Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CGTX: Zervimesine advances toward DLB psychosis registration, with strong data and solid cash position - TradingView
CGTX: Zervimesine advances for DLB psychosis with strong data, regulatory focus, and improved 2025 financials - TradingView
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress - TipRanks
Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial By Investing.com - Investing.com India
COGNITION THERAPEUTICS ($CGTX) Releases Q4 2025 Earnings - Quiver Quantitative
Cognition Therapeutics 10-K: Net loss $23.5M, EPS $(0.32) - TradingView
Zervimesine pipeline and grant backing at Cognition (NASDAQ: CGTX) - Stock Titan
Cognition Therapeutics (NASDAQ: CGTX) narrows 2025 loss, funds into Q2 2027 - Stock Titan
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical ... - Caledonian Record
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update - GlobeNewswire
Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Cognition Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Zervimesine Demonstrates Symptom Slowing in Phase 2 SHIMMER Trial for Dementia With Lewy Bodies - Neurology Live
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results - The Globe and Mail
Cognition Therapeutics sets March 26 webcast on 2025 results - Stock Titan
Cognition presents data on dementia drug zervimesine at conference By Investing.com - Investing.com South Africa
CGTX PE Ratio & Valuation, Is CGTX Overvalued - Intellectia AI
Cognition presents data on dementia drug zervimesine at conference - Investing.com
Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 - Bitget
Cognition Therapeutics Presents Promising Phase 2 Results of Zervimesine for Dementia with Lewy Bodies at AD/PD 2026 Conference - Quiver Quantitative
Cognition Therapeutics Presents Evidence of Zervimesine’s - GlobeNewswire
Dementia trial drug slowed neuropsychiatric decline 86% vs placebo - Stock Titan
Cognition Therapeutics (CGTX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Aug Intraday: Can Cognition Therapeutics Inc lead its sector in growthQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
MACD Signal: What is the dividend yield of Cognition Therapeutics IncDividend Hike & AI Based Trade Execution Alerts - baoquankhu1.vn
Cognition Therapeutics shifts focus to DLB psychosis treatment By Investing.com - Investing.com Australia
Cognition Therapeutics shifts focus to DLB psychosis treatment - Investing.com Nigeria
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis - Bitget
Cognition Therapeutics Advances Zervimesine for DLB Psychosis - TipRanks
Cognition Therapeutics, Inc. Announces Advancement of Zervimesine Development for Dementia with Lewy Bodies Psychosis Treatment - Quiver Quantitative
Cognition Therapeutics advancing zervimesine (ct1812) for dementia with Lewy bodies (DLB) psychosis - marketscreener.com
Cognition Therapeutics advances zervimesine as registrational program for DLB psychosis after FDA Type C minutes - TradingView
Cognition Therapeutics Advancing Zervimesine (Ct1812) For Dementia With Lewy Bodies (DLB) Psychosis - TradingView
Zervimesine push: Cognition Therapeutics (NASDAQ: CGTX) targets DLB psychosis - Stock Titan
DLB psychosis often untreated — zervimesine study targets hallucinations - Stock Titan
CGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
COGNITION THERAPEUTICS, INC. (CGTX) Stock, Price, News, Quotes, Forecast and Insights - MSN
Can Cognition Therapeutics Inc disrupt its industryQuarterly Profit Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Is Cognition Therapeutics Inc. stock a safe buy before earningsWeekly Trend Report & High Conviction Trade Alerts - mfd.ru
Whale Trades: Is Cognition Therapeutics Inc stock heavily shortedPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn
CGTX (CGTX) CFO reports tax-withholding share disposition on RSU vesting - Stock Titan
Is Cognition Therapeutics Inc. stock overvalued by current metrics2025 Key Highlights & High Win Rate Trade Alerts - mfd.ru
Why Cognition Therapeutics Inc. stock is recommended by analysts2025 Market WrapUp & Reliable Volume Spike Alerts - mfd.ru
FY2025 Earnings Forecast for CGTX Issued By Brookline Cap M - Defense World
Cognition Therapeutics (NASDAQ:CGTX) Upgraded to Strong-Buy at Brookline Cap M - MarketBeat
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):